Emergent BioSolutions Inc. — Director's Dealing 2025

Mar 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2025-02-12

Reporting Person: LINDAHL RICHARD S (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-12	Common Stock	D	16916	—	Disposed	154093	Direct
2025-02-28	Common Stock	F	1073	$7.48	Disposed	153020	Direct
2025-03-01	Common Stock	F	683	$7.48	Disposed	152337	Direct

Footnotes

F1: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 16,916 shares previously reported on March 1, 2022.

F2: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units